`Risk of cardiovascular disease associated with febuxostat versus allopurinol use in patients with gout: a retrospective cohort study in Korea
Open Access
- 8 November 2022
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 43 (2) , 265-281
Abstract
Febuxostat is the drug used to treat hyperuricemia in patients with gout. Recently, the usage of Febuxostat has been controversial over the side effects in cardiovascular. The study aimed to comparatively analyze the risk of cardiovascular disease associated with febuxostat and allopurinol use in Korean patients with gout. A cohort study was conducted using national insurance claim data from the Health Insurance Review and Assessment Service (HIRA). Adult patients who were diagnosed with gout and prescribed febuxostat or allopurinol more than once from July 1, 2015, to June 30, 2018 were studied. The outcome was cardiovascular disease. Analysis was performed using Cox’s proportional hazard model following 1:1 propensity score matching to estimate the hazard ratio with a 95% confidence interval. In total, 90,590 patients were defined as the final study cohort who had an average follow-up of 467 days, including 28,732 and 61,858 patients in the febuxostat and allopurinol groups, respectively. After the 1:1 propensity score matching, the risk of cardiovascular disease in the febuxostat group was significantly higher than in the allopurinol group (HR: 1.17; 95% CI: 1.10–1.24). In the sensitivity analysis, the risk of cardiovascular disease in the febuxostat group was significantly higher than in the allopurinol group (HR: 1.09; 95% CI: 1.04–1.15). However, further sensitivity analysis showed no statistically significant difference between the febuxostat group and allopurinol group after adjusting for cardiovascular disease history before the index date. Similarly, no statistically significant difference was found between the two drugs in the subgroup analysis. Febuxostat was not associated with a significantly increased risk of cardiovascular disease.Keywords
This publication has 20 references indexed in Scilit:
- Cardiovascular Safety of Febuxostat or Allopurinol in Patients with GoutNew England Journal of Medicine, 2018
- Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA DataJournal of Korean Medical Science, 2017
- Febuxostat: drug review and updateExpert Opinion on Drug Metabolism & Toxicology, 2014
- Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trialArthritis Care & Research, 2008
- Xanthine Oxidase Inhibition With Febuxostat Attenuates Systolic Overload-Induced Left Ventricular Hypertrophy and Dysfunction in MiceJournal of Cardiac Failure, 2008
- Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndromeAmerican Journal of Physiology-Renal Physiology, 2008
- Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: Effects of early versus delayed treatmentLife Sciences, 2008
- Acute Effects of Febuxostat, a Nonpurine Selective Inhibitor of Xanthine Oxidase, in Pacing Induced Heart FailureJournal of Cardiovascular Pharmacology, 2006
- Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and GoutNew England Journal of Medicine, 2005
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983